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Abstract
Background/Aim: Fas/FasL system is a major regulator of apoptosis. The mechanisms by which Fas mediates cisplatin 
resistance remain unclear. The aim of this study is to explore the effect of Fas over-expression on cisplatin resistance of 
small cell lung cancer cells and its possible mechanisms.
Materials and methods: Fas was over-expressed in H446/CDDP cells by infection with the adenoviruses containing 
Fas. Sensitivity of Fas-overexpressed H446/CDDP cells to cisplatin was evaluated using MTT assay. Expressions of Fas, 
GST-π and ERCC1 were detected by RT-PCR and Western blot analysis. Apoptosis rate was examined by FACS.
Results: Over-expression of Fas in H446/CDDP cells significantly decreased the expressions of GST-π and ERCC1 at 
mRNA and protein levels, and increased the cell apoptosis. Furthermore, up-regulation of Fas significantly decreased 
the tolerance of H446/CDDP cells to cisplatin.
Conclusion: Over-expression of Fas reverses drug resistance of H446/CDDP cells, possibly due to the increased cell 
sensitivity to apoptosis and the decreased expressions of GST-π and ERCC1.
Background
Small cell lung cancers (SCLC) are well known for their
initial sensitivity to chemotherapeutic agents and thereaf-
ter frequent recurrence when tumors exhibit drug resis-
tance. Cisplatin, formally known as cis-
diamminedichloroplatinum (II) (CDDP), is a metal-base
oncolitic agent that binds to the nucleophilic sites of
DNA resulting in changes in DNA synthesis and cell
death [1]. For this reason, cisplatin is commonly recom-
mended for chemotherapeutical treatment of SCLC.
However, many patients with SCLC exhibit drug resis-
tance, which hampers the outcomes of cisplatin treat-
ment.
It is well known that a number of cellular adaptations,
including reduced drug uptake, drug inactivation by glu-
tathione and other antioxidants, increased levels of DNA
repair enzymes or DNA tolerance, and altered drug tar-
gets could cause resistance to CDDP, which may contrib-
u t e  t o  t h e  p o o r  s u r v i v a l  r a t e  o f  S C L C  p a t i e n t s .
Dysfunction of apoptotic signal transduction pathway of
malignant cells can also cause drug resistance. For exam-
ple, down-regulation of pro-apoptotic genes such as Bax
and Fas/FasL and up-regulation of anti-apoptotic genes
such as Bcl-2 has been involved in drug resistance. Fas, a
45 kDa type I transmembrane protein, is expressed on
cell membranes of varieties of normal cells and malignant
cells including lung cancer cells [2,3]. Its ligand, FasL, is
expressed on the cell membrane of activated T lympho-
cytes and some malignant cells [4,5]. After trimerization
of Fas on the cell membrane by extracellular FasL [6], Fas-
associated death domain (FADD) and caspase 8 bind to
the intracellular death domains of Fas and induce a death
signal in the cells [7], leading to the activation of a cas-
cade of caspases and eventually to cell death. Since FasL
can induce apoptosis in Fas-expressing malignant cells,
the Fas/FasL system plays an important role in T cell-
mediated cytotoxic reaction and malignant cell-mediated
autocrine suicide or paracrine death against malignant
cells. On the other hand, malignant cells can avoid being
killed by down-regulating Fas expression. It has been
demonstrated that cisplatin-resistant lung cancer cells
express low level of Fas, and correspondingly, their apop-
tosis decreases significantly. Some reports have corre-
lated multidrug resistance (MDR) with the decreased Fas
expression and resistance to Fas-mediated apoptosis. Fas-
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resistant cells were resistant to chemotherapeutic drug
treatment, which is presumably due to the disruption of
pathways responsible for the induction of cell death by
chemotherapeutic drugs [8].
Many agents can induce the expression of Fas, and thus
promote the apoptosis of malignant cells. Cisplatin can
enhance some solid tumors or leukaemic cell surface
expression of Fas [9-11] via the activation of the acid
sphingomyelinase (aSMase) and the generation of cer-
amide at the plasma membrane. Up-regulating the
expression of melanoma differentiation-associated gene-
7/interleukin-24 (MDA-7/IL-24) can enhance the expres-
sion of Fas activated by cisplatin. Cisplatin can also
enhance MDA-7/IL-24 toxicity via activation of the
extrinsic pathway and de novo ceramide synthesis [12].
Bruno Segui et al proposed that it might be a way to treat
cancer by enhancing the expression of Fas and promoting
the apoptosis of tumor cell [13]. But in cisplatin-resistant
human squamous cell carcinomas of the head and neck
(SCCHN) cells, although the expression of Fas was
enhanced by cisplatin or IFN-γ, the cisplatin sensitivity
cannot be restored by agonistic Fas-antibodies [14]. How-
ever, the agonistic Fas-antibodies could restore the cispla-
tin sensitivity in other entities like bladder carcinomas
[15]. Many factors may be involved, including that: 1.
High expression of drug-resistance genes such as gluta-
thione S-transferase π (GST-π) and excision repair cross-
complementing-1 (ERCC1) may be the major mechanism
of drug resistance, and Fas-FasL system may be a minor
one; 2. In SCCHN, the expression of Fas activated by cis-
platin is p53-independent and may be ineffective activa-
tion, which was in contrast to many other solid tumors,
where the antiproliferative effect of anticancer drugs is
mediated at least in part by the Fas-FasL system via p53-
dependent mechanisms [16].
It is still obscure whether up-regulation of Fas expres-
sion can reverse cisplatin resistance, increase cisplatin-
induced apoptosis, and alter the expression of any drug-
resistant gene in human SCLC cells. To explore the possi-
ble role of Fas on cisplatin resistance in SCLC cells, we
established a cisplatin-resistant SCLC cell line (H446/
CDDP), and constructed adenovirus vector containing
Fas gene. By overexpressing Fas, we investigated the role
of Fas in cisplatin sensitivity and apoptotic rate of SCLC
cells. We also examined the levels of GST-π and ERCC1,
given their involvement in drug binding/inactivation and
nucleotide excision repair (NER). Our results indicate
that up-regulation of Fas could reverse cisplatin resis-
tance of human SCLC cells by decreasing the expressions
of GST-π and ERCC1 and increasing Fas-mediated apop-
tosis.
Methods
Cell lines and culture conditions
Cisplatin was obtained from Ebewe Arzneimittel
Ges.m.b.H. (Austria). Human SCLC cell line H446 was
obtained from Academy of Military Medical Science
(Beijing, China) and maintained in RPMI 1640 (Trace,
Melbourne, Australia) supplemented with 10% fetal
bovine serum (FBS), 100 U/ml penicillin, and 100 μg/ml
streptomycin at 37°C, in a humid atmosphere of 5% CO2/
95% air . Exposing them to gradually increasing concen-
trations of cisplatin (up to 30.8 μg/ml) induced in vitro
cisplatin-resistant cells. The obtained cell sublines H446/
CDDP were maintained in the absence of drug, and its
drug resistance was stabilized by 30.8 μg/ml CDDP treat-
ment for 4 days every 6 weeks. H446/CDDP is 39.0 times
as resistant to cisplatin as its parental cell line. Cells from
exponentially growing cultures were used for all experi-
ments.
Adenovirus vector construction and gene transduction
Total RNA was extracted from H446 cells and first strand
of cDNA was synthesized, the open reading frame (ORF)
of human Fas gene was cloned using the primers with
restriction endonuclease site as following: up primer 5'
GGGGTACC ATGCTGGGCATCTGGACCCTC 3'(Kpn
I) and 5' GCTCTAGA TCACTCTAGACCA-
AGCTTTGG 3' (Xba  I). PCR reaction was performed
with 5 min of initial denaturation at 94°C, 30 cycles of 30
s denaturation at 94°C, 30 s annealing at 61°C, 45 s exten-
sion at 72°C, and finally 10 min extension at 72°C. The
PCR product of target fragment about 1013 bp was puri-
fied and ligased into T-vector, and the positive bacteria
c o l o n i e s  w e r e  s c r e e n e d  f o r  s e q u e n c i n g  b y  a m p i c i l l i n
resistance and blue-white screening with X-gal and IPTG.
The Fas gene was subcloned to pAdTrack-CMV plasmid
(a gift from Gang Huang, Third Military Medical Univer-
sity, Chongqing, China) and recombinants of pAdTrack-
CMV-Fas were generated by transformation the shuttle
plasmid linearized with Pme I to BJ5183 cells with the
adenoviruses backbone plasmid for homologous recom-
bination. The recombinant adenoviruses were packaged
and propagated in 293 cells. Viral titers were determined
by standard plaque assay after the Fas adenoviruses con-
centrated by CsCl ultracentrifugation using a standard
method [17].
H446/CDDP cells were transfected with 50 multiplicity
of infection (MOI) of adenoviruses in serum free RPMI
and maintained in complete medium at 37°C until post-
transfection day 3. The transfectants overexpressing Fas
were obtained and designated as H446/CDDP/Fas. H446/
CDDP cells transfected with empty adenoviruses were
indicated as H446/CDDP/Empty and used as negative
control in all assays.Wu et al. Journal of Experimental & Clinical Cancer Research 2010, 29:49
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Conventional RT-PCR analysis
On post-transfection day 3, total RNAs were isolated
from H446/CDDP, H446/CDDP/empty, and H446/
CDDP/Fas cells using TRIzol reagent (TianGen, Beijing,
China) and subsequently used for semiquantitative PCR.
RT was performed with 1 μg of total RNA from each sam-
ple using oligo(dT) 18 primers and 200 units of Super-
Script II RT (Life Technologies Inc., Gaithersburg, Md.,
USA) for cDNA synthesis. cDNA amplification was con-
ducted in 20 μl solution containing 2 μl of diluted cDNA,
10 pmol primer pairs for Fas, GST-π, ERCC1 and
GAPDH, respectively, and 10 μl of Taq PCR Master mix
(TianGen, Beijing, China). The PCR consisted of initial
denaturation at 94°C for 5 min, followed by 30 reaction
cycles (30 seconds at 94°C, 30 seconds at 61°C, and 30
seconds at 72°C) and a final cycle at 72°C for 10 min.
Primers used in PCR were listed in Table 1. GAPDH was
used as internal control. All PCR products were electro-
phoretically separated on ethidium bromide-stained aga-
rose gel and visualized with UV light.
Real-time quantitative PCR (RT-qPCR)
RT-qPCR was performed with ABI 7500 Thermal Cycler
and SYBR Green qPCR kit (Toyobo, Japan). PCR reac-
tions were prepared in low-profile microplates with each
well containing 10 μl of master mix, 2 μl of diluted cDNA,
10 pmol each of primers listed in Table 1 for Fas, GST-π,
ERCC1 and control GAPDH, respectively, in a 20 μl reac-
tion volume. The PCR consisted of initial denaturation at
94°C for 5 min, followed by 30 reaction cycles (30 seconds
at 94°C, 30 seconds at 61°C, and 30 seconds at 72°C) and a
final cycle at 72°C for 10 min. Amplifications were per-
formed in triplicate according to the cycling protocol
provided by the manufacturer. Gene expression was
expressed as 2-ΔΔ(Ct) [18], where Ct is cycle threshold,
Δ(Ct) = Ct of tested gene - Ct of GAPDH; ΔΔ(Ct) = Δ(Ct)
of sample 1-Δ(Ct) of sample 2.
Western blot analysis
The mouse anti-human Fas (cat. sc-74540), GST-π (cat.
sc-58368) and rabbit anti-human ERCC1(cat. sc-10785)
antibodies and horseradish peroxidase(HRP)-conjugated
goat anti-rabbit and goat anti-mouse immunoglobulin G
(IgG) were obtained from Santa Cruz Biotechnology
(Santa Cruz, Calif., USA). 5 × 106 H446/CDDP Cells were
seeded into 100 mm plates, incubated for 24 h at 37°C,
and then transfected with 50 MOI of adenoviruses. On
post-transfection day 3, H446/CDDP, H446/CDDP/Fas,
and H446/CDDP/empty cells were washed three times
with cold phosphate buffered saline (PBS) and then lysed
in RIPC buffer (0.5 M NaCl, 0.5% NP-40, 20 mM Tris-
HCl pH 8, 1 mM PMSF). The protein levels were deter-
mined using an ECL kit ((Amersham Pharmacia, Upp-
sala, Sweden). Total cellular proteins were diluted 2-fold
into SDS-PAGE loading buffer (NEB). The samples were
heated to 95°C for 5 min before an aliquot of 20 μl of each
diluted assay sample, containing approximately 50 ug of
total protein, was loaded onto a 6-12% Tris-glycine poly-
acrylamide gel (Invitrogen). Proteins were resolved by
SDS-PAGE and then transferred to a 0.45 μm nitrocellu-
lose membrane (Whatman). The membrane was blocked
with 5% nonfat dry milk in Tris-buffered saline (50 mM
Tris-HCl, pH 7.5, 150 mM NaCl) supplemented with
0.2% Tween 20 and 0.05% Triton X-100 (TBSTT). The
membrane was probed with the primary antibody at
1:700 dilution in TBSTT supplemented with 2% nonfat
dry milk. After an overnight incubation at 4°C, the mem-
brane was washed and incubated at room temperature for
2 h with a goat anti-rabbit or mouse HRP-linked IgG anti-
body (1:700 dilution in TBSTT with 2% dry milk). Bind-
ing of the antibody was detected by chemiluminescence
with the Phototope-HRP Western Blot Detection System
(CST).
In vitro drug sensitivity assay
Drug sensitivity was evaluated using 3-(4,5-dimethylthi-
azol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT)
Table 1: PCR primer sequences and product sizes.
Primersa Oligonucleotide Sequences Product Size (bp) PCR Cycles
Fas F: 5'GTCCAAAAGTGTTAATGCCCAAGT 3' 232 30
R: 5'ATGGGCTTTGTCTGTGTACTCCT 3'
GST-π F: 5' CCGCCCTACACCGTGGTCTAT 3' 260 30
R: 5' GCTGCCTCCTGCTGGTCCTT 3'
ERCC1-2 F: 5' ACGCCGAATATGCCATCTCAC 3' 292 30
R: 5' AGCCGCCCATGGATGTAGTCT 3'
GAPDH F: 5' ACCCATCACCATCTTCCAGGAG 3' 159 30
R: 5' GAAGGGGCGGAGATGATGAC 3'
a All primers were designed using genetool software.Wu et al. Journal of Experimental & Clinical Cancer Research 2010, 29:49
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assay. Briefly, on post-transfection day 3, the transfected
cells and control cells were seeded into 96-well plates
with 103 cells per well and incubated overnight. Cells
were then incubated with CDDP in different concentra-
tions (5, 10, 15, 20, 25, 30, 35, 40, 45, and 50 μg/ml). After
72 h of incubation, 20 μl of 5 mg/ml MTT (Sigma Chemi-
cal Co., St Louis, MO) in PBS was added to each well, fol-
lowed by incubation for 4 h at 37°C. The formazan
c r y s t a l s  w e r e  d i s s o l v e d  i n  5 0  μ l  o f  d i m e t h y l  s u l f o x i d e
(DMSO). The optimal density was determined with
microculture plate reader (Becton Dickinson Labware,
Lincoln Park, NJ) at 570 nm. Absorbance values were
normalized to the values obtained for control cell to
determine the proportion of survival [19]. The IC50 val-
ues were the drug concentrations causing a 50% reduc-
tion in the optical density. The experiments were
performed in triplicate, and expressed as the mean values
of three experiments.
The relative resistance was calculated by the following
formula:
Apoptosis analysis
On post-transfection day 3, cells were resuspended in 100
μl binding buffer at a concentration of 1 × 106/ml after
washing twice with cold PBS and mixed with 5 μl
Annexin V-FITC (PharMingen) and 10 μl of 20 μg/ml
propidium iodide (Sigma) at room temperature for 15
min. Samples were diluted with 400 μl binding buffer and
analyzed by fluorescence activated cell sorting (FACS)
using the protocol provided by the manufacturer (Clon-
Tech, Palo Alto, Calif., USA). The apoptotic rate was cal-
culated as the mean fluorescence intensity.
Statistical analysis
The data are expressed as the mean ± SEM. Each experi-
ment was repeated at least three times. Bands from West-
ern blots were quantified by Quantity One software (Bio-
Rad). The differences among means were examined with
ANOVA followed by post-hoc test using SPSS 11.0 soft-
ware (Chicago, Ill., USA). A p value less than 0.05 was
considered as statistical significance.
Results
RT-PCR and Western blots
Both mRNA and protein levels of Fas were significantly
lower in H446/CDDP and H446/CDDP/Empty cells com-
pared with those in H446/CDDP/Fas cells (p < 0.01), indi-
cating that Fas was successfully transduced into and
expressed in H446/CDDP cells. Over-expression of Fas
effectively down-regulated ERCC1 and GST-π in both
mRNA and protein levels (p < 0.01) compared with the
control cells (Figs. 1 and 2).
Effect of Fas on cisplatin resistance
To explore the roles of Fas in cisplatin resistance of SCLC,
MTT assays were performed. 72 h after exposure to
CDDP, the 50% inhibitory concentration (IC50) of CDDP
in H446/CDDP/Fas was 7.6 ± 0.46 μg/ml, significantly
lower than 30.8 ± 0.92 μg/ml and 29.7 ± 0.26 μg/ml in
H446/CDDP and H446/CDDP/Empty, respectively (p <
0.01). In other words, H446/CDDP/Fas cells showed a
3.9-fold decrease in resistance to CDDP compared with
H446/CDDP/Empty cells, suggesting that up-regulation
of Fas could inhibit the cisplatin-resistant phenotype of
SCLC.
Effect of Fas on cell apoptosis
The apoptosis rates in H446/CDDP, H446/CDDP/Empty
and H446/CDDP/Fas cells were 6.02 ± 0.70%, 7.19 ±
0.89% and 13.17 ± 0.40%, respectively. Compared to
H446/CDDP and H446/CDDP/Empty cells, H446/
Relative resistance IC  of H CDDP Fas cells IC  of = (/ / ) / ( 50 50 446    H CDDP Empty cells 446 / / ).
Figure 1 The expression of Fas, ERCC1, GST-π and GAPDH detect-
ed by RT-qPCR. GAPDH was used as an internal control. Upregulation 
of Fas led to a significant decrease in ERCC1 and GST-π. * p < 0.01 vs 
H446/CDDP/Empty and H446/CDDP cells.Wu et al. Journal of Experimental & Clinical Cancer Research 2010, 29:49
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CDDP/Fas cells showed a significantly lower apoptotic
rate (p < 0.01, Fig. 3), suggesting that the up-regulation of
Fas promoted the apoptosis in H446/CDDP cells.
Discussions
As one of the most widely used platinum-containing anti-
c a n c e r  d r u g s ,  C D D P  i s  b e l i e v e d  t o  i n d u c e  t u m o r  c e l l
death as a result of the formation of CDDP-DNA
adducts, which inhibits DNA replication and transcrip-
tion [20]. The presence of intrinsic or acquired resistance
to CDDP in cancer cells limits curative effects of chemo-
therapy. Therefore, understanding the precise mecha-
nisms of CDDP resistance and reversing it would provide
new strategies for cancer therapy.
The balance of Fas/FasL interaction between the host
immune system and malignant cells may be crucially
involved in determining sensitivity or resistance towards
chemotherapy. In several malignant cell lines, including
SCLC cell lines, commonly used chemotherapeutic drugs
have been shown to induce Fas expression [21]. Cisplatin
can promote apoptosis of malignant cells by inducing Fas
expression, which is one of the mechanisms of cisplatin
killing the malignant cells. For instance, cisplatin could
up-regulate expressions of Fas and FasL, activate caspase
8 pathways and induce apoptosis in uterine cervix cancer
cells [22]. Matsuzaki I et al [23] found that cisplatin could
induce Fas expression in esophageal cancer cell lines and
enhance cytotoxicity in combination with LAK cells. Lan
F. Qin et al [24] found that cisplatin could induce expres-
sion of Fas in hepatoma cells, which was correlated with
the appearance of cisplatin-induced apoptosis. But the
cisplatin-resistant malignant cells usually express low
level of Fas, and correspondingly, the apoptosis of malig-
nant cells decreases significantly. Fas-resistant cells are
resistant to chemotherapeutic drug treatment, which is
presumably due to the disruption of the pathway respon-
sible for cell death induced by chemotherapeutic drugs
[25]. In our study, the enhanced mRNA and protein
expressions of Fas in cisplatin-resistant SCLC cells corre-
spondingly increases SCLC cell apoptosis.
The mechanisms of resistance to CDDP are multifacto-
rial, and many genes or gene products have been report-
edly responsible for CDDP resistance [26]. Cisplatin is
most efficiently removed from transcribed areas within
DNA, and gene-specific repair efficiency of cross-links
correlates with cisplatin resistance [27]. Platinum damage
is repaired primarily by the nucleotide excision repair
(NER) system (particularly ERCC1 and ERCC1/XPF) and
the related genes XPA and BRCA1 [28,29]. Previous stud-
ies have found that increased expression of ERCC1, an
important NER protein, is correlated with CDDP resis-
tance. For instance, expression of ERCC1 has been shown
to increase the resistance to platinum treatment in
patients with ovarian cancer [30]. Similarly, non-small
cell lung carcinoma (NSCLC) displayed a correlation
between CDDP resistance and ERCC1 levels [31-33]. Tes-
ticular cancer, generally very responsive to CDDP, has
low level of ERCC1, providing further correlative evi-
dence for the importance of ERCC1 in CDDP resistance
[34]. Given its involvement in the NER DNA repair path-
way, we paid special attention to ERCC1. A previous
study has proved that the suppression of ERCC1 expres-
sion in human cancer cells leads to an increased sensitiv-
ity to CDDP, and ERCC1 has been presumed to be an
attractive target to confer increased cellular sensitivity to
CDDP-based chemotherapy [35]. The results of this study
suggest that the expression of ERCC1 is significantly
down-regulated with the transfection of Fas in H446/
CDDP cells, which may contribute to the decreased resis-
tance to CDDP.
Increased glutathione (GSH) may cause resistance by
binding/inactivating cisplatin, enhancing DNA repair, or
reducing cisplatin-induced oxidative stress [36]. Glutathi-
one-S-transferase (GST), particularly GST-π [37,38], may
augment drug resistance by catalyzing GSH-drug bind-
ing. Clinically, GST-π gene amplification [39], immunos-
taining [40], and plasma levels [41] have been correlated
with cisplatin resistance, suggesting that platinum detoxi-
fication by GSH and GST may be clinically important.
The results of this study suggest that the expression of
GST-π is significantly down-regulated with the transfec-
Figure 2 The expression of Fas, ERCC1, and GST-π detected by 
Western blots. β-actin was used as an internal control. Upregulation 
of Fas caused the downregulation of ERCC1, and GST-π.Wu et al. Journal of Experimental & Clinical Cancer Research 2010, 29:49
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tion of Fas in H446/CDDP cells, which may contribute to
the decreased resistance to CDDP.
Conclusion
Our results show that Fas gene transduction can reverse
the multidrug resistance (MDR) of human drug resistant
SCLC cell H446/CDDP, for which the enhanced cell sen-
sitivity to apoptosis and decreased expression of GST-π
and ERCC1 may be responsible. Although the biological
function of Fas in SCLC needs to be further investigated,
the present results of our study provide a framework for
the illumination of the resistance to CDDP mediated by
Fas, and will aid in the effective use of CDDP in SCLC
treatment.
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